They suggested that the beneficial effect of compounds of the cGMP pathway to relieve nephrogenic diabetes insipidus may be improved when combined with agents that stimulate AQP2 expression [20]. The gene discussed is AQP2; the disease is nephrogenic diabetes insipidus.